Galactosylceramides

"Galactosylceramides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Cerebrosides which contain as their polar head group a galactose moiety bound in glycosidic linkage to the hydroxyl group of ceramide. Their accumulation in tissue, due to a defect in beta-galactosidase, is the cause of galactosylceramide lipidosis or globoid cell leukodystrophy.

Descriptor ID	D005699
MeSH Number(s)	D02.065.313.250.450 D09.400.410.420.525.200.250.450 D10.390.470.675.200.250.450 D10.570.877.360.612.200.250.450
Concept/Terms	Galactosylceramides Galactosylceramides Galactosyl Ceramides Ceramides, Galactosyl Galactocerebrosides

Below are MeSH descriptors whose meaning is more general than "Galactosylceramides".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Amides [D02.065]
Ceramides [D02.065.313]
Cerebrosides [D02.065.313.250]
Galactosylceramides [D02.065.313.250.450]
Carbohydrates [D09]
Glycoconjugates [D09.400]
Glycolipids [D09.400.410]
Glycosphingolipids [D09.400.410.420]
Neutral Glycosphingolipids [D09.400.410.420.525]
Ceramides [D09.400.410.420.525.200]
Cerebrosides [D09.400.410.420.525.200.250]
Galactosylceramides [D09.400.410.420.525.200.250.450]
Lipids [D10]
Glycolipids [D10.390]
Glycosphingolipids [D10.390.470]
Neutral Glycosphingolipids [D10.390.470.675]
Ceramides [D10.390.470.675.200]
Cerebrosides [D10.390.470.675.200.250]
Galactosylceramides [D10.390.470.675.200.250.450]
Membrane Lipids [D10.570]
Sphingolipids [D10.570.877]
Glycosphingolipids [D10.570.877.360]
Neutral Glycosphingolipids [D10.570.877.360.612]
Ceramides [D10.570.877.360.612.200]
Cerebrosides [D10.570.877.360.612.200.250]
Galactosylceramides [D10.570.877.360.612.200.250.450]

Below are MeSH descriptors whose meaning is related to "Galactosylceramides".

Below are MeSH descriptors whose meaning is more specific than "Galactosylceramides".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Galactosylceramides" by people in this website by year, and whether "Galactosylceramides" was a major or minor topic of these publications.

Bar chart showing 9 publications over 7 distinct years, with a maximum of 2 publications in 2005 and 2009

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2001	1	0	1
2002	0	1	1
2005	1	1	2
2009	1	1	2
2010	1	0	1
2013	0	1	1
2014	0	1	1

Below are the most recent publications written about "Galactosylceramides" by people in Profiles.

Pierce BG, Vreven T, Weng Z. Modeling T cell receptor recognition of CD1-lipid and MR1-metabolite complexes. BMC Bioinformatics. 2014 Sep 26; 15:319.

View in: PubMed
Tatituri RV, Watts GF, Bhowruth V, Barton N, Rothchild A, Hsu FF, Almeida CF, Cox LR, Eggeling L, Cardell S, Rossjohn J, Godfrey DI, Behar SM, Besra GS, Brenner MB, Brigl M. Recognition of microbial and mammalian phospholipid antigens by NKT cells with diverse TCRs. Proc Natl Acad Sci U S A. 2013 Jan 29; 110(5):1827-32.

View in: PubMed
Sada-Ovalle I, Sköld M, Tian T, Besra GS, Behar SM. Alpha-galactosylceramide as a therapeutic agent for pulmonary Mycobacterium tuberculosis infection. Am J Respir Crit Care Med. 2010 Sep 15; 182(6):841-7.

View in: PubMed
Scheuplein F, Rissiek B, Driver JP, Chen YG, Koch-Nolte F, Serreze DV. A recombinant heavy chain antibody approach blocks ART2 mediated deletion of an iNKT cell population that upon activation inhibits autoimmune diabetes. J Autoimmun. 2010 Mar; 34(2):145-54.

View in: PubMed
Chopra P, Diiorio P, Pino SC, Wilson SB, Phillips NE, Mordes JP, Rossini AA, Greiner DL, Shultz LD, Bortell R. Failure of alpha-galactosylceramide to prevent diabetes in virus-inducible models of type 1 diabetes in the rat. In Vivo. 2009 Mar-Apr; 23(2):195-201.

View in: PubMed
Dougan SK, Salas A, Rava P, Agyemang A, Kaser A, Morrison J, Khurana A, Kronenberg M, Johnson C, Exley M, Hussain MM, Blumberg RS. Microsomal triglyceride transfer protein lipidation and control of CD1d on antigen-presenting cells. J Exp Med. 2005 Aug 15; 202(4):529-39.

View in: PubMed
Chen YG, Choisy-Rossi CM, Holl TM, Chapman HD, Besra GS, Porcelli SA, Shaffer DJ, Roopenian D, Wilson SB, Serreze DV. Activated NKT cells inhibit autoimmune diabetes through tolerogenic recruitment of dendritic cells to pancreatic lymph nodes. J Immunol. 2005 Feb 01; 174(3):1196-204.

View in: PubMed
Chackerian A, Alt J, Perera V, Behar SM. Activation of NKT cells protects mice from tuberculosis. Infect Immun. 2002 Nov; 70(11):6302-9.

View in: PubMed
Riese RJ, Shi GP, Villadangos J, Stetson D, Driessen C, Lennon-Dumenil AM, Chu CL, Naumov Y, Behar SM, Ploegh H, Locksley R, Chapman HA. Regulation of CD1 function and NK1.1(+) T cell selection and maturation by cathepsin S. Immunity. 2001 Dec; 15(6):909-19.

View in: PubMed
Mercurio AM, Schwarting GA, Robbins PW. Glycolipids of the mouse peritoneal macrophage. Alterations in amount and surface exposure of specific glycolipid species occur in response to inflammation and tumoricidal activation. J Exp Med. 1984 Oct 01; 160(4):1114-25.

View in: PubMed

People

Explore

Similar Concepts

Top Journals